Certara (NASDAQ:CERT) Receives Market Perform Rating from William Blair

Certara (NASDAQ:CERT)‘s stock had its “market perform” rating reissued by investment analysts at William Blair in a report released on Thursday,RTT News reports.

CERT has been the subject of a number of other reports. TD Cowen initiated coverage on shares of Certara in a research report on Thursday. They issued a “buy” rating and a $16.00 target price for the company. Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday. Barclays lowered their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $15.64.

Certara Price Performance

Shares of CERT traded down $0.40 during trading hours on Thursday, hitting $11.93. 412,697 shares of the stock were exchanged, compared to its average volume of 1,245,412. The stock’s 50-day moving average price is $12.39 and its two-hundred day moving average price is $11.63. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -60.00, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara has a 12-month low of $9.41 and a 12-month high of $19.87.

Hedge Funds Weigh In On Certara

A number of hedge funds have recently made changes to their positions in the stock. Venturi Wealth Management LLC raised its position in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after buying an additional 1,047 shares during the period. Blue Trust Inc. lifted its stake in Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after acquiring an additional 2,076 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in Certara during the 4th quarter worth about $47,000. Finally, KBC Group NV boosted its holdings in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.